Beroni Pharmaceutical has received approval from the Environmental Impact Report Form of the Zhuhai Ecological Environment Bureau
The “Environmental Impact Report for the Anti-cancer Drug PENAO Project and Cell R&D and Transformation Project” (hereinafter referred to as the “Project”) submitted by the subsidiary of Beroni Group, Beroni…
Beroni Group was Invited to Attend the 4th World-Class Enterprises R&D and Innovation Management Forum
On September 8th, 2023, the “4th World-Class Enterprises R&D and Innovation Management Forum” was successfully held in Huabei Hotel, Hangzhou. Mr. Qingrui Xu, Academician of Chinese Academy of Engineering, Director…
Successful Conclusion to the Conference of FET
On 24th July, the second plenary session of the first members’ conference of the Federation of Entrepreneurs Tianjin was held in the Tianjin Auditorium. Mr. Jacky Zhang, Executive Chairman of…
Beroni and Shenyang University Of Chemical Technology Successfully Signed the Practice Base Agreement
On March 31st, the signing ceremony of a Practice Base Agreement between Tianjin Beroni Biotechnology Co., Ltd., a subsidiary of Beroni Group and Shenyang University of Chemical Technology was held…
Beroni Group Advances Research and Development of its Enhanced COVID-19 Antigen Rapid Test Kit
On February 8, 2023, Beroni Group Limited (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced that its enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method has…